Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study
Background: The European Organization for Research and Treatment of Cancer (EORTC) 62012 study was a Phase III trial of doxorubicin versus doxorubicin-ifosfamide chemotherapy in 455 patients with advanced soft tissue sarcoma (STS). Analysis of the main study showed that combination chemotherapy impr...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
21 Apr 2017
|
| In: |
Acta oncologica
Year: 2017, Jahrgang: 56, Heft: 7, Pages: 1013-1020 |
| ISSN: | 1651-226X |
| DOI: | 10.1080/0284186X.2017.1315173 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1080/0284186X.2017.1315173 Verlag, Volltext: https://doi.org/10.1080/0284186X.2017.1315173 
|
| Verfasserangaben: | Robin J. Young, Saskia Litière, Michela Lia, Pancras C.W. Hogendoorn, Cyril Fisher, Gunhild Mechtersheimer, Søren Daugaard, Raf Sciot, Françoise Collin, Christina Messiou, Viktor Grünwald, Alessandro Gronchi, Winette van der Graaf, Eva Wardelmann, Ian Judson |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1580127924 | ||
| 003 | DE-627 | ||
| 005 | 20220814223221.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180816s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/0284186X.2017.1315173 |2 doi | |
| 035 | |a (DE-627)1580127924 | ||
| 035 | |a (DE-576)510127924 | ||
| 035 | |a (DE-599)BSZ510127924 | ||
| 035 | |a (OCoLC)1341017171 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Young, Robin J. |e VerfasserIn |0 (DE-588)1164727516 |0 (DE-627)1029015929 |0 (DE-576)510127789 |4 aut | |
| 245 | 1 | 0 | |a Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy |b a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study |c Robin J. Young, Saskia Litière, Michela Lia, Pancras C.W. Hogendoorn, Cyril Fisher, Gunhild Mechtersheimer, Søren Daugaard, Raf Sciot, Françoise Collin, Christina Messiou, Viktor Grünwald, Alessandro Gronchi, Winette van der Graaf, Eva Wardelmann, Ian Judson |
| 264 | 1 | |c 21 Apr 2017 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published online: 21 Apr 2017 | ||
| 500 | |a Gesehen am 16.08.218 | ||
| 520 | |a Background: The European Organization for Research and Treatment of Cancer (EORTC) 62012 study was a Phase III trial of doxorubicin versus doxorubicin-ifosfamide chemotherapy in 455 patients with advanced soft tissue sarcoma (STS). Analysis of the main study showed that combination chemotherapy improved tumor response and progression-free survival, but differences in overall survival (OS) were not statistically significant. We analyzed factors prognostic for tumor response and OS, and assessed histological subgroup and tumor grade as predictive factors to identify patients more likely to benefit from combination chemotherapy.Methods: Central pathology review was performed by six reference pathologists. Gender, age, performance status, time from first presentation with sarcoma to starting palliative chemotherapy, tumor grade, histological subgroup, primary tumor site involvement, and sites of metastases were assessed as prognostic factors.Results: Three hundred and ten patients were included in this study. Discordance between local and central pathology opinion of tumor histology and tumor grade was observed in 98 (32%) and 122 (39%) cases, respectively. In multivariate analysis, liposarcoma patients had improved tumor response compared to other histological subgroups, whilst patients with metastases other than lung, liver or bone had a poorer response [odds ratio (OR) 0.42, 95% confidence interval (CI) 0.23-0.78; p = 0.006]. Patients with bone metastases had reduced OS [hazard ratio (HR) 1.56, 95% CI 1.16-2.09; p = 0.003]. By central pathology review, patients with undifferentiated pleomorphic sarcoma (UPS) had improved tumor response and OS with doxorubicin-ifosfamide compared to single-agent doxorubicin (OR 9.90, 95% CI 1.93-50.7 and HR 0.44, 95% CI 0.26-0.79, respectively). Grade III tumors had improved response with combination chemotherapy but there was no interaction between chemotherapy and grade on OS.Conclusions: Prospective central pathology review of tumor histology should be integrated into future STS clinical trials. Doxorubicin-ifosfamide may be most appropriate for young, fit patients with poorly differentiated Grade III tumors including UPS. | ||
| 700 | 1 | |a Mechtersheimer, Gunhild |e VerfasserIn |0 (DE-588)1021953024 |0 (DE-627)715842595 |0 (DE-576)170441598 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Acta oncologica |d Abingdon : Taylor & Francis Group, 1987 |g 56(2017), 7, Seite 1013-1020 |h Online-Ressource |w (DE-627)302725490 |w (DE-600)1492623-4 |w (DE-576)082435367 |x 1651-226X |7 nnas |a Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study |
| 773 | 1 | 8 | |g volume:56 |g year:2017 |g number:7 |g pages:1013-1020 |g extent:8 |a Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/0284186X.2017.1315173 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://doi.org/10.1080/0284186X.2017.1315173 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180816 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 1021953024 |a Mechtersheimer, Gunhild |m 1021953024:Mechtersheimer, Gunhild |d 910000 |d 912000 |e 910000PM1021953024 |e 912000PM1021953024 |k 0/910000/ |k 1/910000/912000/ |p 6 | ||
| 999 | |a KXP-PPN1580127924 |e 3022486499 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"21 Apr 2017"}],"person":[{"role":"aut","family":"Young","given":"Robin J.","display":"Young, Robin J."},{"given":"Gunhild","display":"Mechtersheimer, Gunhild","role":"aut","family":"Mechtersheimer"}],"note":["Published online: 21 Apr 2017","Gesehen am 16.08.218"],"title":[{"subtitle":"a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study","title_sort":"Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy","title":"Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy"}],"id":{"doi":["10.1080/0284186X.2017.1315173"],"eki":["1580127924"]},"recId":"1580127924","name":{"displayForm":["Robin J. Young, Saskia Litière, Michela Lia, Pancras C.W. Hogendoorn, Cyril Fisher, Gunhild Mechtersheimer, Søren Daugaard, Raf Sciot, Françoise Collin, Christina Messiou, Viktor Grünwald, Alessandro Gronchi, Winette van der Graaf, Eva Wardelmann, Ian Judson"]},"physDesc":[{"extent":"8 S."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"relHost":[{"id":{"zdb":["1492623-4"],"eki":["302725490"],"issn":["1651-226X"]},"note":["Gesehen am 12.12.2023","Fortsetzung der Druck-Ausgabe"],"title":[{"title_sort":"Acta oncologica","title":"Acta oncologica"}],"recId":"302725490","physDesc":[{"extent":"Online-Ressource"}],"disp":"Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 studyActa oncologica","origin":[{"publisher":"Taylor & Francis Group ; Scandinavian Univ. Press ; Taylor & Francis ; Informa Healthcare","dateIssuedKey":"1987","dateIssuedDisp":"1987-","publisherPlace":"Abingdon ; Oslo ; London [u.a.] ; London [u.a.]"}],"language":["eng"],"pubHistory":["26.1987 -"],"type":{"bibl":"periodical","media":"Online-Ressource"},"part":{"pages":"1013-1020","volume":"56","extent":"8","text":"56(2017), 7, Seite 1013-1020","issue":"7","year":"2017"}}]} | ||
| SRT | |a YOUNGROBINPREDICTIVE2120 | ||